Bionano Genomics Announces Participation at the 2022 American Cytogenomics Conference (ACC) and a User Spotlight Event at Augusta University, a Center of Excellence for OGM
- For the first time at this conference, Bionano will exhibit all of its cytogenetic research solutions: OGM solutions, NxClinical software and laboratory services
- In a dedicated OGM scientific session, six presentations will illustrate the application of Bionano’s OGM in prenatal and postnatal testing, constitutional disease, and cancer
- Dr.
Soheil Shams , chief informatics officer of Bionano, will present a scientific session on Analytical Tools to Support Detection of Homologous Recombination Deficiency (HRD) Using Cytogenomic Scar Markers - Dr.
Alex Hastie , vice president of clinical affairs at Bionano, will host a sponsored vendor presentation on integrating OGM and next generation sequencing (NGS) for a comprehensive analysis of the genome - Following the conference, Bionano will host a user spotlight event at an OGM center of excellence at the
Georgia Esoteric Molecular Laboratory atAugusta University
ACC is a biennial conference that brings together industry and academic professionals to discuss new technologies and advances in the field of cytogenetics. ACC sessions will take place
Dr. Solheil Shams, chief informatics officer at Bionano, will present on the utilization of three new measures of genomic instability available in NxClinical v6.2 software to detect homologous recombination repair deficiency (HRD) in solid tumors. In a spotlight talk immediately following the OGM scientific session, Dr.
At the conclusion of ACC, Bionano will host an interactive tour of an OGM center of excellence at the
Scientific presentations and poster sessions from Bionano and collaborators include:
Title | Presenters/Authors | Presented |
Analytical Tools to Support Detection of Homologous Recombination Deficiency (HRD) Using Cytogenomic Scar Markers |
Shams S | |
Comparative Benchmarking of Optical Genome Mapping to Chromosomal Microarray Reveals High Technological Concordance in CNV Identification and additional Structural Variant Refinement |
Pang AWC, Barseghyan H, Chaubey A, Hastie A |
|
Optical Genome Mapping as a Potential Tier1 Test for Postnatal Chromosomal Disorders – Results of Multi-Institutional Validation Study of 331 Retrospective Clinical Samples |
Iqbal M, Broeckel U, Levy B, Skinner S, Sahajpal N, Rodriguez V, Stence A, Awayda K, Scharer G, Skinner C, Stevenson R, Bossler A, Nagy P, Kolhe R |
|
Optical Genome Mapping for Prenatal Diagnostic Testing |
Sahajpal N, Mondal A, Fee T, Hastie A, Chaubey A, DuPont B, Kohle R |
|
Optical Genome Mapping Analysis of FMR1 Expansions in Fragile X Syndrome |
Barseghyan H, Muggli M, Ramandi B, Miller N, Zhang D, Lam E, Wang J, Wang T, Lee J, Pang AWC, Sadowski H, Hastie A, Oldakowski M |
|
Optical Genome Mapping Workflow for Identification and Annotation of Variants in Hematological Malignancy |
Clifford B, Hauenstain J, Pang AWC, Chaubey A, Hastie A |
|
Capture-Based Transcriptome Sequencing (RNA-Seq) and Optical Genome Mapping (OGM) Enhance Detection of Newly Described Molecular Subtypes of Pediatric B-lymphoblastic Leukemia (B-ALL) |
Raca G, Kovach A, Doan A, Ostrow D, Yellapantula V, Ji J, Schmidt R, Biegel J, Bhojwani D |
|
Find More Answers: Integrating NGS and OGM for a Comprehensive Analysis of the Genome |
Hastie A | |
GDA-Cyto: Infinum Arrays Propel Heights |
Saul D, Hagan J |
All presentations and poster sessions will be held in the
“The lineup of content that will be presented on Bionano’s solutions at ACC this year is world class. What makes our participation unique this year, is that we will have the combination of OGM products and our NxClinical software for attendees to view. We are focused on addressing their needs and now we can show them how, in person. After the show, we will be hosted at
About
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “potentially,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential contribution of our OGM and software solutions in the analysis of genetic diseases and cancer or the use of software solutions for homologous recombination repair deficiency (HRD) detection. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support additional studies, adoption or continued use of our technologies; the ability of our OGM, NxClinical software and laboratory services solutions to offer the anticipated benefits for and contributions to pre and postnatal genomic analysis, cancer research, structural variant analysis as well as other areas of research; future study results contradicting the results reported in the presentations given and posters made available at ACC; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomic

Source: Bionano Genomics